Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) have been assigned an average recommendation of "Hold" from the thirteen brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $101.70.

A number of equities research analysts have commented on the company. Cowen lowered their target price on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Piper Sandler lowered their target price on Tandem Diabetes Care from $120.00 to $80.00 and set an "overweight" rating on the stock in a report on Thursday, August 4th. StockNews.com cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a report on Friday. Lake Street Capital reduced their price target on Tandem Diabetes Care from $200.00 to $150.00 in a research note on Thursday, August 4th. Finally, Cowen reduced their price target on Tandem Diabetes Care from $141.00 to $107.00 in a research note on Thursday, August 4th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TNDM. Fifth Third Bancorp raised its position in shares of Tandem Diabetes Care by 358.3% in the 2nd quarter. Fifth Third Bancorp now owns 440 shares of the medical device company's stock worth $26,000 after buying an additional 344 shares during the period. Quadrant Capital Group LLC raised its position in shares of Tandem Diabetes Care by 244.7% in the 2nd quarter. Quadrant Capital Group LLC now owns 517 shares of the medical device company's stock worth $31,000 after buying an additional 367 shares during the period. Exane Derivatives purchased a new position in shares of Tandem Diabetes Care in the 1st quarter worth $33,000. Byrne Asset Management LLC purchased a new position in Tandem Diabetes Care in the fourth quarter valued at about $34,000. Finally, CI Investments Inc. raised its position in Tandem Diabetes Care by 10,566.7% in the first quarter. CI Investments Inc. now owns 320 shares of the medical device company's stock valued at $37,000 after purchasing an additional 317 shares during the period. 95.28% of the stock is owned by hedge funds and other institutional investors.

Tandem Diabetes Care Stock Performance

About Tandem Diabetes Care

(Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More

• Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks
• The Auto Market Is Slowly Recovering, These Stocks May Outperform
• Is DocuSign On The Verge Of A Major Reversal?
• Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.